Ticker LaunchIPO · GRAY
CalciMedica, Inc.
Formerly CalciMedica, Inc. /DE/; GRAYBUG VISION, INC.; GRAYBUG, Inc.
CalciMedica, Inc. (GRAY) priced its initial public offering on Sep 25, 2020 at $16.00 per share, within its $15.00–$17.00 range, raising $90M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $321.5M. Leerink Partners was lead-left underwriter, joined by Piper Sandler, Needham and Wedbush. Fenwick & West advised the company and WilmerHale advised the underwriters.
At its 2020 IPO, Graybug Vision, Inc. (now CalciMedica, Inc.) was a clinical-stage biopharmaceutical company developing medicines for retina and optic nerve diseases, using controlled-release technology. Its lead candidate, GB-102, is an intravitreal injection of a microparticle depot.
- Status
- IPO
- Ticker
- GRAY
- Exchange
- Nasdaq Global Market
- Priced
- Sep 25, 2020
- IPO price
- $16.00
- Price range
- $15.00–$17.00
- Raised
- $90M
- Market cap at IPO price
- $321.5M
- First filed
- Sep 4, 2020
- Underwriters
- Leerink Partners, Piper Sandler, Needham and Wedbush
- Company counsel
- Fenwick & West
- Underwriters' counsel
- WilmerHale
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Sep 4, 2020
- Latest amendment Sep 21, 2020
- Final prospectus (424B4) Sep 25, 2020
- All filings on EDGAR CIK 1534133
Other Biotech & pharma IPOs in 2020
- Orphazyme A/SORPH · Sep 29, 2020 · $83.8M
- Greenwich LifeSciences, Inc.GLSI · Sep 28, 2020 · $7.3M
- PMV Pharmaceuticals, Inc.PMVP · Sep 25, 2020 · $211.8M
- Prelude Therapeutics IncPRLD · Sep 25, 2020 · $158.2M
- Taysha Gene Therapies, Inc.TSHA · Sep 25, 2020 · $157.4M
- COMPASS Pathways plcCMPS · Sep 21, 2020 · $127.5M